A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

NCT04893759 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Company Strategy

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Pelcitoclax

Sponsor

Ascentage Pharma Group Inc.